A recent study found that measuring circulating tumor cells (CTCs) is a reliable way to predict later treatment response and survival prospects in men when…
Category: News
A team of researchers at the University of Southern California has used a commercial blood test to count circulating tumor cells (CTCs) and predict how…
A blood test that measures the number of circulating tumor cells (CTCs) at the time of metastatic prostate cancer diagnosis can predict treatment response, disease…
In metastatic hormone-sensitive prostate cancer (mHSPC), new first-line combination therapies have enhanced overall survival (OS), but clinical outcomes for individual patients vary greatly and are…
October 07, 2024 “Prostate cancer is the most common malignancy [among] American men and the second most lethal,” Amir Goldkorn, MD, professor of medicine and biochemistry & molecular…
The non-invasive test, which measures circulating tumor cells in the blood, can predict treatment response, disease progression and overall survival in men newly diagnosed with…
The February issue of National Geographic magazine featured an article providing readers with a broad overview of what liquid biopsies are and what they have…
By Hinde Kast (Originally posted at USC Norris Cancer) Cancer can evolve and adapt during therapy, leading to resistance and progression. New non-invasive technologies can…
“Drs. Amir Goldkorn, Timothy Triche, and Vinay Duddalwar awarded a new multi-investigator R01 grant from the National Cancer Institute for translational biomarker studies in advanced…